L-3,4-Dihydroxyphenylalanine (L-dopa)-induced dyskinesia affects virtually every patient with Parkinson disease (PD) after chronic administration. 1 The pathophysiology of dyskinesia is complex, and several nondopaminergic systems are involved. 2 The serotonin (5-HT) system has received much attention over the past years as a critical player underlying dyskinesia and as a potentially efficacious therapeutic target. 5-HT neurons contain the required enzymes to synthesize dopamine from L-dopa 3 but without the regulatory mechanisms required for dopaminergic transmission, resulting in dysregulated, nonphysiologic dopamine release, which underlies the dyskinetic state. 4 However, if this aberrant dopamine release by 5-HT fibers is the culprit in dyskinesia, it is also responsible, at least partly, for the antiparkinsonian action of L-dopa. 5 As a result, it has proven difficult to achieve an antidyskinetic benefit with agonists of the 5-HT 1A receptors, which act by dampening this aberrant dopamine release by 5-HT terminals, without hindering the therapeutic effect of L-dopa in both preclinical and clinical settings. 6, 7 In this issue of Neurology ® , Lee et al. 8 discover that in patients with PD with dyskinesia, the 5-HT transporter (SERT) to dopamine transporter (DAT) binding ratio is increased in the putamen compared with patients with PD treated with L-dopa but without dyskinesia and patients with PD who are L-dopa-naive. The SERT/DAT binding ratio was also increased in the globus pallidus of L-dopa-treated patients with PD, both dyskinetic and nondyskinetic, when compared with L-dopa-naive patients. Moreover, the putaminal and pallidal SERT/DAT ratios positively correlated with total Unified Parkinson's Disease Rating Scale score and disease duration. These increases in the SERT/DAT ratios were due to declines in both SERT and DAT binding potentials, with the DAT reduction being greater than the SERT decline.
The findings of this study are important, as they may provide a way to determine when dyskinesia will begin at the clinical level. Thus, the study by Lee et al. suggests that beyond a certain threshold SERT/DAT binding ratio within the putamen, dyskinesia will be present; under that threshold, which has yet to be determined, dyskinesia will be absent. Hypothetically, this threshold may represent the tipping point at which dopamine released by 5-HT fibers is quantitatively greater than dopamine released by the remaining dopaminergic fibers, so the dopamine release becomes nonphysiologic and fluctuates widely in concentration.
At the clinical level, if patients with PD were to undergo regular [
11 C]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ( 11 C-DASB) and N-(3-[ 18 F]fluoropropyl)-2-carbomethoxy-3-(4-iodophenyl) nortropane PET scans to have their putaminal SERT/DAT binding ratio assessed, it might be possible to begin administering agents that could delay, or even prevent, the emergence of dyskinesia, were such agents to exist and be clinically available. Needless to say, such an approach would have to take into consideration the financial costs of PET scan examinations and, among other things, the fact that patients would have to undergo 2 such scans at regular intervals (which have yet to be determined). Affordability and practicability limit its use, at least at present. It would be interesting, therefore, to conduct studies to assess the longitudinal progression of the SERT/DAT ratio in cohorts of control individuals, nondyskinetic and dyskinetic L-dopatreated patients with PD, and drug-naive patients with PD. Perhaps this ratio could also be used to predict other manifestations of PD, such as gait difficulty, or the best time to begin dopaminergic therapy based on the patient's pattern of 5-HT and dopaminergic degeneration. Ultimately, this might result in a bespoke therapy that would be more efficacious with fewer treatment-related complications and adverse events.
This enthusiasm has to be mitigated in light of the existing literature. Whereas the study by Lee et al. is in agreement with a previous in vivo imaging study that demonstrated that the striatal SERT/DAT binding ratio may be increased in the dyskinetic state, 9 it is difficult to reconcile with other studies that addressed the fate of the SERT in dyskinesia. For example, a postmortem study conducted in L-dopa-treated patients with PD with and without dyskinesia found increased SERT binding levels in the putamen of dyskinetic patients compared with nondyskinetic patients, 10 in contrast to the findings reported here. Differences in disease duration and in the radioligands used might explain part of this discrepancy, as patients were older in the postmortem study and 3 H-citalopram was used instead of 11 C-DASB. In contrast, a recently published PET study using 11 C-DASB did not demonstrate alterations in binding between dyskinetic and nondyskinetic L-dopa-treated patients with PD. No matter how interesting and promising the results from Lee et al. are, they will need to be replicated in larger studies encompassing a group of healthy, nonparkinsonian individuals. Further studies are therefore required to clarify the fate of the SERT in patients with PD with dyskinesia and to determine how it can be used, as part of the SERT/ DAT ratio or not, as a marker or a predictor of L-dopa-induced dyskinesia.
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